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http://dx.doi.org/10.1016/j.ccell.2015.02.006SUMMARYMany tumor cells are fueled by altered metabolism and increased glutamine (Gln) dependence. We identify
regulation of the L-glutamine carrier proteins SLC1A5 and SLC38A2 (SLC1A5/38A2) by the ubiquitin ligase
RNF5. Paclitaxel-induced ER stress to breast cancer (BCa) cells promotes RNF5 association, ubiquitination,
and degradation of SLC1A5/38A2. This decreases Gln uptake, levels of TCA cycle components, mTOR
signaling, and proliferationwhile increasing autophagy and cell death.Rnf5-deficientMMTV-PyMTmammary
tumors were less differentiated and showed elevated SLC1A5 expression. Whereas RNF5 depletion in MDA-
MB-231 cells promoted tumorigenesis and abolished paclitaxel responsiveness, SLC1A5/38A2 knockdown
elicited opposing effects. Inverse RNF5hi/SLC1A5/38A2lo expression was associated with positive prognosis
in BCa. Thus, RNF5 control of Gln uptake underlies BCa response to chemotherapies.INTRODUCTION
The ER stress (ERS) response plays a critical role in normal
cellular homeostasis by governing cell commitment to survival
or death in response to internal or external cues (Ron andWalter,
2007; Tabas and Ron, 2011). ERS homeostasis is maintained
through the unfolded protein response (UPR), an adaptive intra-
cellular signaling pathway that responds to stress stimuli (Wang
et al., 2010). Notably, ERS pathway components are deregulated
in almost every pathological disorder, including metabolic,
neurodegenerative, and inflammatory diseases and cancer
(Hotamisligil, 2010). Resolution of the ERS response and UPR,
which are induced by specific chemotherapeutic drugs, is
achieved by commitment to survival, autophagy, or death pro-
grams (Meusser et al., 2005; Ogata et al., 2006).Significance
Understanding the mechanisms underlying tumor cell respons
tients for personalized treatment. Here, we identify two glutam
that undergo ubiquitination-dependent degradationmediated b
by specific chemotherapies (illustrated here by paclitaxel). O
reduced, resulting inmTOR inhibition and activation of autopha
of RNF5 in antagonizing tumor development, progression, and
mouse models. RNF5hi/SLC1A5lo expression is associated w
possible stratification of BCa patients for therapies.
354 Cancer Cell 27, 354–369, March 9, 2015 ª2015 Elsevier Inc.Several dedicated ubiquitin ligases play critical roles in the
ERS response and UPR. One of those is RNF5, an ER-associ-
ated E3 ubiquitin ligase that regulates stability and clearance
of proteins functioning in various cellular processes. RNF5 is
part of the UBC6e/p97 network, which are key components of
ER-associated degradation (ERAD) (Bernasconi et al., 2013).
RNF5 contributes to clearance of misfolded proteins (Grove
et al., 2011; Younger et al., 2006). Increased RNF5 expression
is linked to advanced breast cancer (BCa) (Bromberg et al.,
2007).
Intracellular Gln levels are controlled by membrane-anchored
glutamine (Gln) transporters that mediate uptake of small
aliphatic amino acids such as L-Gln (Taylor et al., 2003). L-Gln
is a critical nutrient for cancer cells (Medina, 2001), serving as
a carbon and nitrogen source for synthesis of macromoleculesiveness to therapy is expected to allow stratification of pa-
ine carrier proteins, SLC1A5 and SLC38A2 (SLC1A5/38A2),
y the ubiquitin ligase RNF5 in response to ER stress induced
nce the carrier proteins are degraded, glutamine uptake is
gy and cell death programs.Wedemonstrate the importance
response to therapy using human BCa tissues and genetic
ith luminal type BCa and improved prognosis, pointing to
and, via conversion to a-ketoglutarate, as an ATP source through
the tricarboxylic acid cycle (TCA) cycle and oxidative phosphor-
ylation. L-Gln metabolism is transcriptionally regulated by Myc
(Gao et al., 2009; Wise et al., 2008), which also suppresses
microRNA-23a/b to enhance expression of the glutaminase 1
(GLS1) (Liu et al., 2012).
Among Gln transporters, SLC1A5 is highly expressed in BCa
cells and is also implicated in regulation of essential amino
acid influx, mammalian target of rapamycin (mTOR) activation
(Nicklin et al., 2009), and L-Gln-dependent tumor cell growth
(Hassanein et al., 2013). Moreover, SLC1A5 inhibition in hepa-
toma and acute myeloid leukemia cells attenuates mTORC1
signaling, resulting in growth repression and apoptosis (Fuchs
et al., 2007; Willems et al., 2013), suggesting a role in cellular
transformation (Witte et al., 2002). Mechanisms underlying
control of SLC1A5-mediated L-Gln uptake in tumor cells and
implications for the tumor cell response to therapy are largely un-
known (DeBerardinis et al., 2007). The glutamine transporter
SLC38A2 is more ubiquitously expressed, although elevated
SLC38A2 expression has been reported in prostate tumors
(Okudaira et al., 2011). Intracellular L-Gln levels maintained by
both SLC1A5 and SLC38A2 (SLC1A5/38A2) in turn modulate
activity of the amino acid exchanger SLC7A5/SLC3A2 and pro-
mote leucine uptake (Baird et al., 2009), with a concomitant ef-
fect on mTOR signaling (Evans et al., 2008).
Here, we set out to determine the role of RNF5 in the control
of two L-Gln transporters, SLC1A5/38A2, and its implications
for L-Gln uptake and BCa response to therapy.
RESULTS
SLC1A5/38A2 Are RNF5 Substrates
To identify RNF5 substrate(s) in BCa cells, we overexpressed a
FLAG-tagged catalytically inactive RING mutant form of RNF5
(RNF5 RM) in the human BCa cell line MCF7. Coimmunopreci-
pitating proteins (Figure S1A) were subjected to liquid chroma-
tography-tandem mass spectrometry (LC-MS/MS) analysis,
which identified peptides corresponding to SLC1A5/38A2 pro-
teins (data not shown). To confirm interaction of SLC1A5/38A2
with RNF5, we performed immunoprecipitations (IPs) using
exogenous and endogenous proteins. SLC1A5/38A2 bound
to both wild-type (WT) RNF5 and RNF5 RM, but not to RNF5
DCT, which lacks the C-terminal transmembrane domain (Fig-
ures 1A and 1B). These findings confirm association of RNF5
with SLC1A5/38A2 and demonstrate that the RNF5 membrane
anchor is required for the interaction, consistent with RNF5
interactions with other substrates (Kuang et al., 2012). To deter-
mine whether RNF5 ubiquitinates SLC1A5/38A2, we co-ex-
pressed SLC1A5 or SLC38A2 with hemagglutinin (HA)-tagged
ubiquitin plus WT, RM, or DCT forms of RNF5. Both SLC1A5
and SLC38A2 were ubiquitinated by WT RNF5, but not by
RNF5 RM or RNF5 DCT (Figures 1C and 1D), indicating that
ligase activity and membrane anchor are required for RNF5 ef-
fects on these Gln carrier proteins. Accordingly, steady-state
levels of SLC1A5 or SLC38A2 proteins decreased as RNF5
levels increased (Figures 1E and 1F). Degradation of SLC1A5
or SLC38A2 by RNF5 was blocked in cells treated with the pro-
teasome inhibitor MG132 (Figures 1E and 1F), consistent with
RNF5-induced ubiquitination of SLC1A5 and SLC38A2, result-ing in proteasome-mediated degradation. LC-MS/MS analysis
also identified the bi-directional transporter SLC3A2 as a puta-
tive RNF5-interacting protein. Although IP analysis confirmed
RNF5 interaction with SLC3A2 (Figure S1B), RNF5 did not pro-
mote SLC3A2 ubiquitination (Figure S1C). To determine
whether RNF5 activity alters SLC1A5 half-life, HEK293T cells
were co-transfected with SLC1A5 plus WT, RM, or DCT RNF5
and then treated with the translational inhibitor cycloheximide
for varying times. As expected, ectopically expressed WT
RNF5, but not RM or DCT, decreased SLC1A5 half-life from 8
to 2 hr (Figures 1G and 1H). These findings demonstrate that
RNF5 association leads to ubiquitination and degradation of
SLC1A5/38A2.
ERS Promotes RNF5/SLC1A5 Association and
RNF5-Dependent Ubiquitination and Degradation
of SLC1A5 in BCa Cells
We next searched for conditions favoring RNF5 regulation
of SLC1A5 in BCa cells. Treatment of MDA-MB-231 (human
triple-negative) BCa cells with three well-established ERS in-
ducers—brefeldin A (BFA), tunicamycin (TM), or thapsigargin
(TG)—promoted a marked and time-dependent decrease in
SLC1A5 levels (Figure 2A). Since TG was less potent in regu-
lating Gln carrier proteins than BFA or TM, we assessed the ef-
fect of increasing TG doses and demonstrate a corresponding
dose-dependent decrease in the levels of SLC1A5/38A2 (Fig-
ure S2). Co-incubation of cells with MG132 attenuated BFA
effects, suggesting that SLC1A5 undergoes proteasome-depen-
dent degradation in response to ERS (Figure 2B). Consistent with
this finding, BFA treatment decreased SLC1A5 half-life from >8
to 2.5 hr (Figure 2C).
Given that ERS-inducing agents reduce SLC1A5 stability, we
assessed a potential role for RNF5 in this process. Notably, inter-
action of SLC1A5 with RNF5 increased in BFA-teated cells (Fig-
ure 2D) and in paclitaxel-treated cells (Figure 2E). BFA-induced
SLC1A5 ubiquitination decreased following RNF5 knockdown
(KD) relative to control small hairpin RNA (shRNA)-treated cells
(Figure 2F). Likewise, BFA-, TM-, or TG-induced SLC1A5 desta-
bilization decreased following RNF5 depletion (Figure 2G).
Notably, among the three ERS inducers, BFA treatment pro-
moted the most pronounced decrease in SLC1A5 levels. Since
BFA promotes retrograde transport of proteins from the Golgi
to the ER, it may increase SLC1A5 accumulation in the ER,
thereby enhancing its interaction with RNF5. Collectively, these
findings establish regulation of SLC1A5 stability by RNF5 in
response to ERS.
ERS-Induced, RNF5-Mediated SLC1A5/38A2
Degradation Decreases Glutamine Uptake, mTOR
Signaling, and BCa Cell Growth
Using gas chromatography (GC)-MS analysis, we observed that
restoration of the Gln pool (to cells that were deprived of gluta-
mine followed by replenishment by glutamine-rich media)
occurred rapidly (Figure S3A). The steady-state Gln levels
(reached within 1 hr) did not differ appreciably between cells
with perturbed versus unperturbed uptake machinery. Owing
to the slower conversion of glutamine to glutamate, we chose
to assess glutamate and downstream metabolites in cells that
were subjected to KD of RNF5, SLC1A5, or SLC38A2 individuallyCancer Cell 27, 354–369, March 9, 2015 ª2015 Elsevier Inc. 355
Figure 1. RNF5 Ubiquitinates and Destabilizes the Gln Carrier Proteins SLC1A5 and SLC38A2
(A and B) V5-tagged SLC1A5 (SLC1A5-V5) (A) or V5-tagged SLC38A2 (SLC38A2-V5) (B) was transiently co-expressedwith FLAG-tagged RNF5WT, RNF5 RM, or
RNF5 DCT in HEK293T cells. Cells were treated (10 mM MG132, 4 hr) and cell lysates were subjected to IP followed by WB with indicated antibodies.
(C and D) SLC1A5-V5 (C) or SLC38A2-V5 (D) was co-expressed in HEK293T cells with HA-ubiquitin (Ub) plus indicated RNF5 constructs. Cells were treated with
MG132 (10 mM, 4 hr) prior to preparation of lysates and then subjected to IP followed by WB using indicated antibodies. Asterisk indicates immunoglobulin G
heavy chain.
(E and F) HEK293T cells expressing SLC1A5-V5 (E) or SLC38A2-V5 (F) were transfectedwith increasing amounts of FLAG-RNF5WT and treated as indicated with
MG132 (10 mM, 4 hr). WB performed with indicated antibodies.
(G and H) HEK293T cells were transfected with SLC1A5-V5 and either a 33FLAG-tagged control construct or indicated RNF5 constructs and treated with
cycloheximide (CHX; 50 mg/ml) for indicated times. WB performed with indicated antibodies (G), and SLC1A5 protein levels were quantified by densitometry (H).
Bars represent mean values ± SD of three experiments.
See also Figure S1.or in combination. Notably, combined SLC1A5/38A2 KD de-
creased the initial rate of Gln accumulation (Figure 3A). Further-
more, combined KD of SLC1A5/38A2 plus RNF5 KD partially
rescued Gln uptake (Figures 3A and S3B).356 Cancer Cell 27, 354–369, March 9, 2015 ª2015 Elsevier Inc.To complement our assessment of effects of RNF5 on Gln up-
take and conversion to Glu, we used [13C]Gln to allow flux anal-
ysis (without the need for glutamine starvation) of downstream
Gln intermediates. Replacement of the unlabeled intracellular
Figure 2. RNF5 Ubiquitinates and Mediates Degradation of SLC1A5 in Response to ERS
(A) MDA-MB-231 cells were treated with 2.5 mg/ml BFA, 5 mg/ml TM, or 2 mM TG for indicated times. WB performed with indicated antibodies.
(B) MDA-MB-231 cells were treated with BFA (2.5 mM, 24 hr) in the absence or presence of MG132 (10 mM, 4 hr). WB performed with indicated antibodies.
(C) MDA-MB-231 cells were incubated with BFA (2.5 mg/ml, 12 hr) and then treated with CHX (50 mg/ml) for indicated times. Left: WB performed with indicated
antibodies. Right: SLC1A5 protein levels were quantified by densitometry. Bars represent mean values ± SD of three experiments.
(D–F) Cell lysates were prepared from MDA-MB-231 cells treated with 2.5 mg/ml BFA (D) or 100 nM paclitaxel (E) or transfected with indicated shRNA and
incubated with 2.5 mg/ml BFA (F) for indicated times and treated with MG132 for 4 hr before preparation of cell lysates. IP and WB were then performed with
indicated antibodies. Asterisk indicates immunoglobulin G (IgG) heavy chain.
(legend continued on next page)
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Gln pool with steady-state levels of [13C]Gln (Figure S3C) re-
vealed only a minor difference between paclitaxel-treated and
untreated MDA-MB-231 cells (Figure 3B, left graph). Nonethe-
less, monitoring glutamate and downstream TCA intermediates
under these experimental conditions allowed us to identify a sig-
nificant (>30% at the 1-hr time point) decrease in 13C enrichment
of downstream products upon paclitaxel treatment (Figure 3B,
right graph). To substantiate these observations, we used radio-
labeled glutamine ([3H]Gln) in MDA-MB-231 cells where expres-
sion of RNF5 and Gln carrier proteins was altered. To better cap-
ture the changes in intracellular Gln levels, cells were also treated
with 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH),
an inhibitor of glutamine exporter SLC7A5 (Nicklin et al., 2009).
Notably, paclitaxel treatment reduced levels of intracellular [3H]
Gln (Figure 3C). Levels of intracellular [3H]Gln increased in cells
expressing shRNF5 (Figures 3C and S3D), which was attenuated
following paclitaxel treatment; however, the resultant [3H]Gln
levels were still higher than basal [3H]Gln levels. Notably, in the
absence of BCH, changes seen upon paclitaxel before and after
shRNF5 were minimal (Figure S3E), pointing to the rapid export
of intracellular Gln. Significantly, KD of SLC1A5 and SLC38A2
reduced the level of intracellular [3H]Gln before and after pacli-
taxel treatment (Figure 3C), which was further reduced upon
repeated transfection of small interfering SLC38A2 (Figure S3E).
KD of RNF5 in SLC1A5/38A2 KD cells did not affect intracellular
levels in the presence of BCH, yet cause some increase in gluta-
mine levels without BCH (Figure S3E). These results demon-
strate that RNF5 controls the levels of intracellular Gln through
its effect on SLC1A5/38A2 and that reduced glutamine uptake
following paclitaxel treatment is primarily RNF5 and SLC1A5/
38A2 dependent.
As availability of intracellular amino acids controls mTOR ac-
tivity (Kim et al., 2013), we analyzed mTOR signaling upon KD
of RNF5 or SLC1A5 in BFA-treated MDA-MB-231 cells. Phos-
phorylation of mTOR and its targets S6K and 4EBP1 decreased
in control shRNA-expressing cells following BFA treatment,
concomitant with decreased SLC1A5 expression (Figure 3D).
Notably, SLC1A5 KD in the absence of BFA treatment also
blocked activation of mTOR and its downstream targets. In con-
trast, RNF5 KD led to persistent activation of mTOR signaling,
coinciding with SLC1A5 stabilization, an effect attenuated by
simultaneous SLC1A5 KD (Figure 3D).
Given the effect of the RNF5-SLC1A5/38A2 regulatory axis on
Gln metabolism and mTOR activity, we assessed changes in
growth and colony formation of BCa cells with altered levels of
RNF5 and SLC1A5/38A2. Whereas BFA treatment inhibits cell
proliferation, this effect was attenuated by RNF5 KD, but not
by SLC1A5 KD. Notably, simultaneous KD of RNF5 and
SLC1A5 rescued the effects of RNF5 KD alone (Figure 3E). We
obtained similar results when we examined clonogenic growth
of MDA-MB-231 or MCF7 cells after BFA treatment (Figures 3F
and S3F). Once again, the effect of RNF5 KD was attenuated
upon SLC1A5 KD (Figure 3F). Rapamycin treatment suppressed
phosphorylation of S6K and 4EBP1 in BFA-treated cells ex-(G) MDA-MB-231 cells were transfected with shControl or shRNF5 and incubate
performed with indicated antibodies. Right: SLC1A5 protein levels were quantifi
experiments.
See also Figure S2.
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mycin inhibited clonogenic growth of shRNF5-expressing cells,
whereas BFA treatment alone did not (Figure 3H). These results
suggest that RNF5 regulation of SLC1A5 occurs upstream of
mTOR signaling.
RNF5-Dependent Downregulation of SLC1A5
or SLC38A2 in BCa Cells Is Associated with
Paclitaxel-Dependent Protein Misfolding
Next, we examined SLC1A5, SLC3A2, SLC38A2, and RNF5
expression in a set of BCa cell lines (Figure 4A). MCF7, MDA-
MB-231, and SKBR-3 lines showed high RNF5 expression,
whereas expression was lower in MDA-MB-453, MDA-MB-
468, and T47D lines. Notably, we did not observe an inverse rela-
tionship between SLC1A5 or SLC38A2 expression versus RNF5
expression under normal growth conditions. Since we observed
an effect of RNF5 on SLC1A5 and SLC38A2 after exposure to
ERS-inducing treatments, we asked whether treatment with
cisplatin, doxorubicin, or paclitaxel, which are commonly used
BCa chemotherapies, would modulate the RNF5-SLC1A5/
38A2 axis. Using BCa cell lines representing high (MCF7 and
MDA-MB-231) and low (MDA-MB-453 and T47D) RNF5 levels,
we found that SLC1A5 expression markedly decreased in high
RNF5-expressing lines relative to low-expressing lines after
paclitaxel treatment and to a lesser extent following cisplatin or
doxorubicin treatment. SLC38A2 expression was also affected
to greater degree in high RNF5-expressing lines following pa-
clitaxel and doxorubicin treatment and to a lesser degree by
cisplatin (Figure 4B). Consistent with our earlier analysis, we
observed no apparent relationship between RNF5 expression
and a third Gln carrier protein, SLC3A2 (Figure S1C), even fol-
lowing drug treatment (Figure 4B). Differential effects of chemo-
therapeutic drugs on SLC1A5 and SLC38A2 expression in BCa
cells suggest that RNF5 and SLC1A5/38A2 expression may
serve as useful markers for patient stratification and possibly
prognostication.
We next assessed possible mechanisms that may account
for the reduced level of SLC1A5 following doxorubicin and
paclitaxel. First, we excluded the possibility that RNF5 exhibits
different subcellular localization in lines where SLC1A5 levels
were reduced following paclitaxel (Figure S4A). Given that ERS
promotes RNF5-mediated SLC1A5 degradation, we asked
whether paclitaxel induces ERS and found that ERSwas induced
by paclitaxel inMDA-MB-231 cells, but not inMDA-MB-453 cells
(Figure 4C), consistent with effects of paclitaxel on SLC1A5
degradation. Canonical branches of the UPR are mediated by
inositol-requiring enzyme 1 (IRE1a, IRE1b), protein kinase
RNA-like ER kinase (PERK), and activating transcription factor
6 (ATF6) (Hetz et al., 2013; Walter and Ron, 2011). Activated
PERK phosphorylates eukaryotic translation initiation factor 2a
(eIF2a), silencing translation. Treatment of MDA-MB-231 cells
with paclitaxel markedly increased IRE1a and eIF2a phosphory-
lation, without altering levels of chaperones such as binding
immunoglobulin heavy chain-binding protein (BiP), proteind with 2.5 mg/ml BFA, 5 mg/ml TM, or 2 mM TG for indicated times. Left: WB
ed by densitometry. Bars represent mean values ± SD of three independent
Figure 3. RNF5-Mediated SLC1A5 Degradation Downregulates L-Glutamine Uptake, mTOR Signaling, and Cell Proliferation in Response to
ERS
(A) MDA-MB-231 cells transfected with indicated constructs were incubated for 6 hr with media lacking Gln, followed by media supplemented with 1 mMGln for
15 min before cells were harvested. Levels of intracellular L-Gln were quantified using GC-MS. Bars represent the mean ± SD.
(B) MDA-MB-231 cells were incubated with 100 nM paclitaxel for 24 hr and then subjected to incubation in medium containing 1 mM [13C]glutamine
(50% labeled). Intracellular [13C]glutamine and [13C]glutamine-derived metabolites were measured by GC-MS. Bars represent the mean ± SD.
(C) MDA-MB-231 cells transfected with indicated constructs were treated with paclitaxel (100 nM, 18 hr) and BCH (10 mM for 1 hr prior to addition on
radiolabeled Gln) and then incubated in medium containing [3H]Gln (5 mCi/ml, 15 min). Duplicate samples were subjected to liquid scintillation assay. Bars
represent the mean ± SD.
(D)MDA-MB-231cells transfectedwith indicatedconstructswere incubated for indicated timeswithorwithout2.5mg/mlBFA.WBperformedwith indicatedantibodies.
(E) MDA-MB-231 cells transfected with the indicated constructs were incubated with or without BFA for 24 hr. Viable cells were counted using trypan blue
exclusion. Bars represent the mean ± SD of three independent experiments.
(legend continued on next page)
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disulfide isomerase (PDI), or Ero1-La (Figure 4C). Surprisingly,
unlike paclitaxel, doxorubicin treatment did not induce ERS or
alter downstream UPR effectors in MDA-MB-231 cells, suggest-
ing that paclitaxel-induced ERS, but not doxorubicin-induced
ERS, underlies RNF5-dependent SLC1A5 degradation. Consis-
tent with a requirement for ERS in SLC1A5 degradation, neither
doxorubicin nor paclitaxel treatment induced ERS in MDA-MB-
453 cells, suggesting that the ability to activate ERS constitutes
another layer of control of SLC1A5 degradation (Figure 4C). To
further assess a link between RNF5-SLC1A5/38A2 signaling
and UPR, the BCa cell lines MDA-MB-231, MDA-MB-453, and
SKBR-3 were treated with paclitaxel, and then levels of Gln car-
rier proteins were monitored over time. SLC1A5/38A2 levels
markedly decreased following paclitaxel treatment in MDA-
MB-231 cells, but not in MDA-MB-453 cells (Figure 4D). Of inter-
est, SLC1A5/38A2 levels decreased 36 hr after paclitaxel treat-
ment in SKBR-3 cells, although RNF5 levels in these cells are
comparable to those in MDA-MB-231 cells. Assessment of
UPR activation in these cells revealed that while IREa and
eIF2a phosphorylation did not change after paclitaxel treatment
of SKBR-3 cells, they were induced in MDA-MB-231 cells (Fig-
ure 4E). These findings suggest that UPR activation is indispens-
able for RNF5-mediated SLC1A5/38A2 degradation following
paclitaxel treatment. Correspondingly, PERK inhibition attenu-
ated paclitaxel-induced SLC1A5/38A2 degradation in MDA-
MB-231 cells (Figure 4F).
Since RNF5 is implicated in the clearance of misfolded pro-
teins as part of the ERAD response (Tcherpakov et al., 2009;
Younger et al., 2006), we asked whether RNF5 interaction
with Gln-carrier proteins required changes in protein folding
following ERS. To do so, we subjected BCa cells to [35S]methio-
nine/cysteine-based labeling followed by immunopurification of
[35S]SLC1A5 and limited proteolytic cleavage using 2-(20-nitro-
phenylsulfonyl)-3-methyl-3-bromoindolenine (BNPS)-Skatole.
SDS-PAGE analysis followed by autoradiography revealed a
marked decrease in SLC1A5 cleavage before but not after pacli-
taxel treatment (Figures 4G and S4B). These findings suggest
that SLC1A5 undergoes misfolding following ERS, consistent
with RNF5 recognition of misfolded proteins at the ER mem-
brane. RNF5 KD attenuated paclitaxel-induced SLC1A5/38A2
degradation (Figure 4H). Likewise, the half-lives of both
SLC1A5/38A2 increased after RNF5 KD in paclitaxel-treated
MDA-MB-231 cells (Figure 4I).
Since glutamine levels also alter homeostasis of reactive oxy-
gen species (ROS), we determined whether RNF5 control of
SLC1A5/38A2 stability impacts ROS levels. ROS levels were
attenuated in RNF5-depleted cells (Figures 4J and S4C).
Notably, KD of either SLC1A5, SLC38A2, or their combination
did not affect ROS levels, as seen upon KD of RNF5; and the
combined KD of SLC1A5/38A2 and RNF5 prevented the
decrease in ROS levels seen upon KD of RNF5 alone, pointing(F) MDA-MB-231 cells transfected as in (E) were incubated with or without BFA fo
the mean ± SD of three independent experiments.
(G) MDA-MB-231 cells transfected with shControl or shRNF5 were treated with B
indicated antibodies.
(H) MDA-MB-231 cells transfected and incubated with BFA in the absence or pres
violet and counted. Bars represent means ± SD of three independent experimen
See also Figure S3.
360 Cancer Cell 27, 354–369, March 9, 2015 ª2015 Elsevier Inc.to the role of the RNF5-SLC1A5/38A2 pathway in regulating
cellular ROS levels.
RNF5-Mediated SLC1A5 Degradation Promotes
Autophagy andCell Death Programs in Response to ERS
The link between ERS and autophagy, including direct activation
of autophagy genes by the key component of the UPR ATF4
(B’chir et al., 2013; He and Klionsky, 2009) andmTOR as a nega-
tive regulator of autophagy (Blommaart et al., 1995), prompted
us to assess whether RNF5 affects autophagy through control
of SLC1A5/38A2. In support of such a possibility is a previous
report that loss of SLC1A5 activates autophagy (Nicklin et al.,
2009). To this end we monitored changes in levels of autophagy
markers p62 and LC3 in BCa cells with altered expression of
RNF5-SLC1A5/38A2. BFA-treated BCa cells exhibited mTOR
inactivation and reduced levels of p62 as early as 9 hr after treat-
ment, changes that were blocked by shRNF5 expression and
rescued by simultaneous SLC1A5 KD (Figure 5A). Intriguingly,
SLC1A5 KD, either alone or in combination with RNF5 KD, pro-
moted p62 degradation in both the absence and presence of
BFA (Figure 5A), suggesting that RNF5-mediated SLC1A5
degradation enhances ERS-induced autophagy. Consistent
with changes in p62 expression, BFA treatment increased the
number of LC3 punctae (monitored by GFP-microtubule-associ-
ated protein 1 light chain 3 [LC3]), an effect that was significantly
inhibited by RNF5 KD (Figures 5B and 5C). Importantly, SLC1A5
depletion promoted marked increases in the number of GFP-
LC3 punctae in non-treated cells and rescued punctae formation
in shRNF5-expressing cells in the presence and absence of BFA
(Figures 5B and 5C). Rapamycin treatment increased the num-
ber of GFP-LC3 punctae in BFA-treated, shRNF5-expressing
cells, consistent with mTOR being downstream of RNF5 in the
ERS-induced autophagy pathway.
Because high levels of ERS activate apoptosis (Shore et al.,
2011), we asked whether the RNF5-SLC1A5 regulatory axis
could also contribute to ERS-induced apoptosis in MDA-MB-
231 cells. BFA treatment of control cells increased apoptosis
at later time points (i.e., 18–48 hr), an activity attenuated in
shRNF5-expressing cells, but not in shSLC1A5-expressing cells
(Figures 5D and S5A). The effect of RNF5 depletion was attenu-
ated upon simultaneous SLC1A5 KD. Fluorescence-activated
cell sorting (FACS) analysis of BCa cells incubated with BFA re-
vealed that reduced RNF5 expression limited the degree of
apoptosis that could be rescued upon co-depletion of RNF5
and SLC1A5, thereby confirming the requirement for the
RNF5-SLC1A5 regulatory axis in BFA-dependent induction of
apoptosis (Figures 5E and S5B). Furthermore, SLC1A5/38A2
KD was sufficient to promote apoptosis in the absence of pacli-
taxel. Notably, attenuation of apoptosis upon RNF5 depletion
was restored following co-depletion of SLC1A5/38A2 (Figures
5F and S5C). These findings substantiate the importance ofr 7 days. Colonies were stained with crystal violet and counted. Bars represent
FA in the absence or presence of rapamycin (1 mM, 12 hr). WB performed with
ence of rapamycin as in (G). One week later, colonies were stained with crystal
ts.
Figure 4. Paclitaxel-Induced ERS and RNF5-Dependent SLC1A5/38A2 Degradation Is Associated with Protein Misfolding
(A) Cell lysates from BCa lines MCF7, MDA-MB-231 (231), MDA-MB-453 (453), MDA-MB-468 (468), SKBR-3, or T47D were immunoblotted with indicated
antibodies.
(B) Indicated cell lines were incubated with 20 mM cisplatin (Cis), 0.5 mg/ml doxorubicin (Dox), or 100 nM paclitaxel (Pacl) for 24 hr. WB performed with indicated
antibodies.
(C) Indicated cell lines were incubated with doxorubicin or paclitaxel for indicated times. WB performed with indicated antibodies.
(D) Indicated cell lines were incubated with paclitaxel for indicated times. WB performed with indicated antibodies.
(legend continued on next page)
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RNF5-SLC1A5/38A2 in determining BCa response to relevant
chemotherapies. The ability of altered Gln metabolism to induce
autophagy (at earlier time points) and cell death programs (at
later time points) is consistent with studies linking these two pro-
cesses (Marin˜o et al., 2014).
RNF5 Inhibition Promotes Mammary Tumors
in the MMTV-PyMTMouse Model
We next determined whether RNF5 loss affects mammary tumor
development in a genetic mouse model of BCa. To do so, we
crossed C57BL/6 Rnf5/ mice with C57BL/6 mouse mammary
tumor virus-polyoma middle T (MMTV-PyMT), a transgenic
model of BCa that permits the examination of in situ tumor pro-
gression from hyperplasia to metastasis (Fluck and Schaffhau-
sen, 2009). Significantly, mammary tumors from Rnf5/ mice
in this model were generally much less differentiated than those
seen in Rnf5+/+ mice (Figure 6A), suggesting that RNF5 loss pro-
motes tumor development and progression. Immunostaining
with vimentin, a marker of epithelial to mesenchymal transition
(EMT) and of poorly differentiated tumors, confirmed that RNF5
loss is associated with less differentiated tumors and progres-
sion of the EMT program (Figure 6B). Notably, mammary tumors
fromMMTV-PyMT;Rnf5/mice exhibited more robust SLC1A5
expression and contained larger areas of SLC1A5 expression
than did tumors from MMTV-PyMT;Rnf5+/+ mice (Figure 6C).
Consistent with the observations that RNF5-mediated SLC1A5
degradation suppressesmTOR activation (Figure 3D), mammary
tumors from MMTV-PyMT;Rnf5/ mice exhibited higher levels
of phosphorylated S6, a downstream mTOR target (Figure 6D).
RNF5 Expression Is Required for BCa Response
to Paclitaxel Treatment
To confirm the role of RNF5 in BCa development and response to
chemotherapeutic drugs, we generated MDA-MB-231 cells that
stably express shRNF5 (Figure S6A). RNF5 KD enhanced growth
of MDA-MB-231 tumors in BALB/c nude mice relative to control
shRNA-expressing tumors (Figure 6E, top). Furthermore,
shRNF5 expressing tumors no longer responded to paclitaxel
and exhibited elevated SLC1A5/38A2 expression relative to
shControl-expressing tumors (Figure 6E, bottom). To directly
confirm SLC1A5/38A2 function in tumor growth and response
to chemotherapy, we generated MDA-MB-231 cells that stably
express shControl, shSLC1A5+shSLC38A2, or shRNF5+
shSLC1A5+shSLC38A2. Notably, SLC1A5/38A2 KD attenuated
MDA-MB-231 tumor growth (Figures 6F and S6D) and sensitized
tumors to paclitaxel treatment. Interestingly, tumors in which(E) Indicated cell lines were incubated with paclitaxel for indicated times. Cell lys
(F) 231 cells were pretreated without or with 1 mM GSK2606414 (a PERK inhibito
performed with indicated antibodies.
(G) 231 cells were transfected with SLC1A5-V5, treated with DMSO or 100 nM pa
was immunopurified and incubated with BNPS-Skatole in vitro for the indicated
with the aid of ImageJ (NIH) software.
(H) 231 cells were transfected with shControl or two different shRNF5s (#1, #2)
indicated antibodies.
(I) 231 cells transfectedwith shControl or shRNF5were incubated with paclitaxel fo
with indicated antibodies.
(J) 231 cells were transfected with indicated constructs and treated with pa
chlorodihydrofluorescein diacetate) staining. Bars represent means ± SD of thre
See also Figure S4.
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were slightly smaller than SLC1A5/38A2 KD tumors (Figure 6F),
substantiating the important role of RNF5 in the control of these
Gln carrier proteins, while pointing to additional possible effects
elicited upon RNF5 KD in tumors where SLC1A5/38A2 were
already depleted.
Low SLC1A5/38A2 Expression in Tumors Is Associated
with Improved Prognosis in Luminal Type Human BCa
We next assessed the significance of the RNF5-SLC1A5/38A2
regulatory axis using a tissue microarray (TMA) consisting of
538 human BCa cores, all of which had undergone pathological
assessment and included annotated clinical outcome. Of those,
>350 cores enabled high-quality staining with at least one of
the three antibodies (SLC1A5, SLC38A2, and RNF5) that were
used in this analysis (Figure 7A). Among characteristic BCa
markers, a node-negative state was associated with disease-
free survival over 15 years (263 of 538; p value = 7 3 1012;
Figure S7A). Likewise, estrogen receptor (ER) positivity (both
determined based on 2010 American Society of Clinical On-
cology/College of American Pathologists criteria) was also asso-
ciated with good survival over 15 years (252 of 535; p value =
4.3 3 105; Figure S7B). Strikingly, low SLC1A5 expression
was significantly associated with an increase in disease-free sur-
vival (191 of 366 tumors; p value = 7.53 105; Figure 7B). Further-
more, low SLC1A5 and ERpos (119 of 363) or nodesneg (98 of 366)
correlated with good prognosis (Figures S7C and S7D). Further-
more, SLC1A5lo/SLC38A2lo (59 of 255 tumors) was significantly
associated with increased disease-free survival (p value =
0.0068; Figure S7E). Compared with SLC38A2, low SLC1A5
expressionwasmore strongly associated with positive prognosis
(124 of 255 cores; p value= 0.0068; Figure S7E). Lastly,23% (79
of 340 tumors) of BCa tumors exhibited RNF5hi and SLC1A5lo
expression and were associated with better prognosis than tu-
mors expressing high SLC1A5hi and low RNF5lo (p value =
0.00058; Figure 7C). Notably, SLC1A5lo was associatedwith pos-
itive prognosis, even in the presence of RNF5lo, suggesting that
other mechanisms may contribute to SLC1A5lo expression (99
of 340 cases; Figure 7C). The latter may represent RNF5-inde-
pendent mechanisms, as reflected in lower transcription of the
Gln carrier protein (Figure S7F). Significantly, 33.5% (108 of 311
tumors) BCa tumors exhibited RNF5hi and SLC1A5/SLC38A2lo,
a pattern strongly associatedwith increased disease-free survival
(p value = 0.0021; Figure 7D). Consistent with these observations,
analysis of the reverse-phase protein array (RPPA) data obtained
for SLC1A5 on 747 TCGA samples showed that SLC1A5 isates were immunoblotted with indicated antibodies.
r) for 2 hr and then incubated with 100 nM paclitaxel for indicated times. WB
clitaxel for 24 hr, and then subjected to labeling with [35S]Met/Cys. SLC1A5-V5
time points. [35S]SLC1A5 was detected using autoradiography and quantified
followed by incubation with 100 nM paclitaxel for 24 hr. WB performed with
r 24 hr and then treatedwith CHX (50 mg/ml) for indicated times.WB performed
clitaxel for 6 hr. Relative ROS levels were determined by DCFDA (2070-di-
e independent experiments.
Figure 5. RNF5 Regulation of SLC1A5 Promotes Autophagy and Apoptosis in Response to ERS
(A) MDA-MB-231 cells transfected with indicated constructs were incubated with 2.5 mg/ml BFA for indicated times. WB performed with indicated antibodies.
(B) MDA-MB-231 cells stably expressing the indicated constructs were transfected with a GFP-LC3 expression plasmid and incubated with or without 2.5 mg/ml
BFA or with 1 mM rapamycin. Scale bar, 10 mm.
(C) Quantification of GFP-LC3 punctae in cells treated as in (B). Bars represent means of ± SD of triplicate samples of >50 cells analyzed per sample in three
experiments. A two-tailed, unpaired t test was used to calculate significance.
(D)MDA-MB-231 cells transfectedwith indicated constructs were incubatedwith 2.5 mg/ml BFA for 18 hr, and apoptotic cells were counted using a TUNEL assay.
Bars indicate mean values ± SD of three experiments.
(legend continued on next page)
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present at high levels (defined by mean and 2 SD) in approxi-
mately half of basal-like BCa cells as well as a subset of luminal
B BCa cells and at low levels in the newly described reactive
BCa subset (Akbani et al., 2014). Based on an analysis of 205
antibodies, SLC1A5 is co-expressed with proteins involved in
cellular differentiation and polarity, cellular metabolism, and
proliferation and negatively correlated with phosphatidylino-
sitol 3-kinase (PI3K) and mitogen-activated protein kinase
(MAPK) pathway signaling (Figure 7E).We also assessed the rela-
tionship between SLC1A5 expression and responsiveness to
neoadjuvant therapies. Two cohorts of 30 tumors each were ob-
tained from patients receiving a combination of either taxanes
with cisplatin or anthracycline with cyclophosphamide as part
of neoadjuvant therapy. In both groups, relatively high SLC1A5
expression was associated with poor responsiveness to therapy
(data not shown). These observations are consistent with the
poor prognosis associated with high SLC1A5 expression seen
in the TMA and RPPA sets and confirm data obtained in BCa
cultures.
DISCUSSION
Altered metabolism is a hallmark of the genetically and epige-
netically driven global rewiring of signaling pathways in cancer
cells. Thus, a better understanding of molecular mechanisms
underlying these changes should improve our ability to define
their contribution to tumor development, progression, and
response to therapy. Given the intimate link between metabolic
cues and key cellular processes, including ERS, UPR, auto-
phagy, and cell death programs, identifying mechanisms that
characterize specific tumor groups may allow design of person-
alized therapies.
In this study, we identify a role for the ubiquitin E3 ligase RNF5
in regulating L-Gln uptake and mTOR signaling in BCa cells,
thereby advancing our understanding of mechanisms underlying
metabolic and cellular responses to chemotherapy. ERS-
induced protein misfolding likely underlies degradation of
SLC1A5 and SLC38A2 by the ER-bound E3 ligase RNF5, result-
ing in a reduced L-Gln uptake and mTOR signaling, slower
growth, and sensitization of BCa cells to autophagy and cell
death programs. Inhibition of RNF5 in eitherMMTV-PyMTmouse
mammary tumor model or MDA-MB-231 BCa cells promoted tu-
mor growth and, in the case of MDA-MB-231, resistance to
paclitaxel treatment. BCa TMA data revealed that higher
SLC1A5 and lower RNF5 expression coincideswith poorer prog-
nosis and identified a subset of tumors in which high level of
RNF5 coincidedwith poor outcome, consistent with our previous
study (Bromberg et al., 2007). Independent studies showed that
increased SLC38A2 expression upon amino acid starvation
is associated with eIF2a phosphorylation (Gaccioli et al.,
2006), suggesting a possible feedback mechanism controlling
SLC38A2 levels. Notably, increased SLC38A2 expression seen
following hypertonic stress did not require eIF2a phosphoryla-(E) MDA-MB-231 cells transfected with indicated constructs were incubated with
FACS. Bars indicate mean values ± SD of three experiments.
(F) MDA-MB-231 cells transfected with indicated constructs were incubated with
by FACS. Bars indicate mean values ± SD of three experiments.
See also Figure S5.
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pression. Furthermore, while our studies document effects of
ERS-inducing compounds, including TG, on Gln carrier protein
degradation, TG reportedly induces expression of SLC1A5/
38A2 in pancreatic b-cells (Krokowski et al., 2013), suggesting
that regulation of Gln carrier protein is cell-type dependent.
Consistent with complex regulation of Gln carrier proteins is
the observation that ATF4, a key UPR-transducing protein, binds
to the SLC38A2 promoter in HepG2 human hepatoma cells,
albeit without altering transcription (Gjymishka et al., 2008).
The diverse regulation of Gln carrier proteins is consistent with
our observations in cultured BCa cells, TMAs, and RPPAs, where
we identified cohorts potentially regulated by distinct mecha-
nisms and that show different clinical outcomes. Importantly,
the regulatory axis identified here likely represents about a third
of BCa luminal type tumors, supporting consideration of patient
stratification for specific therapies.
Growing evidence supports a role for ERS and UPR in tumor
biology. Proteins associated with UPR are upregulated in
ischemic regions of tumors (Shuda et al., 2003), suggesting
that UPR serves a protective function once tumors outstrip their
vascular supply. UPR also reportedly plays an important role in
Tsc2/ tumors, which show constitutive mTORC1 activity
(Young et al., 2013). In that case, increased UPR seen in hypoxic
Tsc2/ cells deprived of serum lipids was implicated in IRE1-
dependent cell death, which was rescued by addition of unsatu-
rated lipids, arguing for the importance of balanced lipid and
protein synthesis in modulating UPR-dependent cell death pro-
grams. The latter is consistent with our recent finding that fine-
tuning of UPR determines commitment to cell death programs,
a process regulated by the ubiquitin ligase Siah1/2 (Scortegagna
et al., 2014). ERS-induced UPR also appears integral to the
mechanism identified here in which paclitaxel-dependent mis-
folding underlies RNF5 association with and degradation of Gln
carrier proteins. One would predict that RNF5 plays an equally
important role in other tumors in which ERS is triggered by
chemotherapeutic drugs (Carew et al., 2006; Gills et al., 2007;
Phillips et al., 1998).
Our study illustrates that the RNF5-SLC1A5/38A2 pathway is
induced by the ability of paclitaxel, but not doxorubicin, to induce
ERS. Thus, the dependence on Gln uptake may allow one to
distinguish and possibly stratify tumors showing a favorable
response to ERS-based therapy based on the status of these
regulatory components. RPPA analysis confirmed that high
expression of SLC1A5 is associated with basal-like and luminal
B types of BCa, as well poorer responsiveness to therapy,
whereas low SLC1A5 expression coincided with reactive,
luminal type tumors. Along these lines, tumors more dependent
on Gln, such as triple-negative BCa cells (Timmerman et al.,
2013) and melanoma cells (Filipp et al., 2012), could benefit
from therapies that target Gln-pathway components in combina-
tion with other therapies. Our data also show that RNF5-medi-
ated control of Gln carrier proteins does not function in all BCa2.5 mg/ml BFA for 24 hr, stained with Annexin-V-EGFP and PI, and analyzed by
100 nM paclitaxel for 48 hr, stained with Annexin-V-EGFP and PI, and analyzed
Figure 6. RNF5 Loss Gives Rise to Less Differentiated MMTV-PyMT Mammary Tumors, Enhances Human MDA-MB231 BCa Growth, and
Reduces Tumor Responses to Paclitaxel
(A and B) H&E staining (A) or immunohistochemistry (IHC) staining of vimentin (B) of mammary tumors fromMMTV-PyMT;Rnf5+/+ orMMTV-PyMT;Rnf5/mice.
Lower panels show higher-magnification images of insets in upper panels. Scale bars, 100 mm (upper panels); 50 mm (lower panels).
(C) Left: IHC staining of SLC1A5 in mammary tumors from indicated genotypes. Scale bars, 100 mm (upper panels); 50 mm (lower panels). Right: quantification of
SLC1A5 staining. Bars represent mean values ± SD of groups consisting ten mice each.
(D) Left: IHC staining of phospho-S6 ribosomal protein in mammary tumors from indicated genotypes. Scale bars, 100 mm (upper panels); 50 mm (lower panels).
Right: quantification of phospho-S6 ribosomal protein staining. Bars represent mean values ± SD of groups of ten mice.
(E) Top: MDA-MB-231 BCa cells (5 3 106) stably expressing shRNF5 or shControl were injected into nude mice, and mice were monitored weekly for tumor
growth. Animals were subjected to paclitaxel treatment 7 days after injection, as described in Experimental Procedures. Bars represent ± SEM. Bottom: IHC
staining of SLC1A5 or SLC38A2 in tumors generated as indicated in (E). Scale bars, 50 mm.
(F) MDA-MB-231 BCa cells (53 106) stably expressing indicated constructs were injected as indicated, monitored, and treated as in (E). Bars represent ± SEM.
See also Figure S6.
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Figure 7. RNF5 and SLC1A5/38A2 Could Serve as Prognostic Markers in Human BCa
(A) Representative immunostaining of a BCa TMA, depicting high and low levels of RNF5, SLC1A5, and SLC38A2 expression. Scale bar, 100 mm.
(B) Kaplan-Meier curves comparing disease-free survival of BCa patients with tumors expressing high or low levels of SLC1A5 protein (p = 7.5 3 105).
(C) Kaplan-Meier curves comparing survival of BCa patients with tumors expressing high or low RNF5 together with high or low levels of SLC1A5 (p = 0.00058).
(legend continued on next page)
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cells and is associated with positive prognosis in a third of all
BCa specimens evaluated (and half of BCa samples that express
low levels of SLC1A5; reduced transcription of SLC1A5 may un-
derlie regulation in the remaining BCa fraction).
Initial data from cohorts of BCa tumors subjected to neoadju-
vant therapy demonstrate that high levels of SLC1A5 coincided
with poor prognosis. These findings are consistent with our cell
culture and xenograft studies. Noteworthy is that two-thirds of
BCa did not maintain RNF5-control of SLC1A5/38A2, attesting
to its importance as well as for the diverse mechanisms used
by BCa to escape this control process. Mechanisms used to
escape RNF5-mediated control of Gln carrier protein expression
might include RNF5 inactivation or upregulated transcription of
genes encoding SLC1A5/38A2, topics that require further study.
Of note, SLC38A2 is reportedly regulated by the ubiquitin ligase
Nedd4-2, suggesting interplay between RNF5 and Nedd4-2 li-
gases (Hatanaka et al., 2006). Certain tumors may fail to activate
the RNF5-SLC1A5 pathway because they possess defense
mechanisms that more effectively block ERS induction or
engage other pathways (such as androgen signaling); those tu-
mors may benefit from chemotherapies that are not dependent
on ERS induction. Although our study focused on BCa, the
RNF5-SLC1A5/38A2 axis may play an equally important role in
other tumor types, particularly those exhibiting L-Gln addiction
phenotypes.
Overall, regulation of SLC1A5/38A2 by RNF5 represents a
temporally and spatially restricted mechanism to control Gln up-
take, as it occurs following ERS (induced by specific chemother-
apeutic drugs) and is restricted to membrane domains, where
RNF5 is anchored. Our findings substantiate the importance of
altered L-Gln uptake in BCa and reveal a mechanism underlying
regulation of the L-Gln carrier proteins SLC1A5 and SLC38A2 by
the ubiquitin ligase RNF5. Given the clinical implications of low
SLC1A5 and SLC38A2 expression for BCa prognosis and the
role of RNF5 in regulating stability of these proteins, our findings
not only identify a marker potentially useful for BCa patient strat-
ification but also provide a mechanistic basis for differences
in Gln metabolism, a key driver of tumor development and
response to therapy.
EXPERIMENTAL PROCEDURES
Animal Studies
All animal experiments were approved by Sanford-Burnham’s Institutional
Animal Care and Use Committee. Animal care was followed according to insti-
tutional guidelines. Detailed experimental procedures are provided in the Sup-
plemental Experimental Procedures.
Human Tumor Array Analysis and RPPA
The Yale cohort (n = 649, patients diagnosed 1962–1982) was constructed into
a TMA at Yale and represents patients diagnosed at Yale New Haven Hospital.
The follow-up information on cases was obtained from the Yale New Haven
Tumor Registry, the Yale-New Haven Hospital medical records, and the Con-
necticut Death Records. Tissues were collected in accordance with consent
guidelines using protocol 9503008219 issued to David L. Rimm from the
Yale institutional review board (IRB) with patient consent acceptable for the(D) Kaplan-Meier curves comparing survival of BCa patients with tumors expre
SLC38A2 (SLC* indicates conditions in which both SLC1A5 and SLC38A2 prote
(E) Heatmap depicting expression of SLC1A5 among basal-like, HER2-positive,
See also Figure S7.time period of specimen acquisition or waiver of consent. All samples used
in the RPPA analysis were obtained by The Cancer Genome Atlas (TCGA)
under IRB approvals to obtain tissues and share with the TCGA. The RPPA
analysis of the TCGA samples was performed under an MD Anderson Cancer
Center IRB approval.
Plasmids and shRNA
Plasmids expressing FLAG-RNF5, FLAG-RNF5RM, and FLAG-RNF5DCT have
been described previously (Bromberg et al., 2007; Tcherpakov et al., 2009).
Plasmids expressing SLC1A5-V5 and SLC38A2-V5 were purchased from Ari-
zona State University Biodesign Institute. shRNAs were purchased from Open
Biosystems or OriGene. Sequences were as follows: for shRNF5, #1, agc ttt
aca tac tgg aca ctc and #2, gac, aac, ctt, ctc, tct, gct, gat; for shSLC1A5, ttc
act tgt atc aac tca ggc; and for shSLC38A2, aat cca aat gcc tta tat c. The
RNAi Consortium lentiviral pLKO.1 control vector served as the shControl.
The human SLC38A2 siGENOME SMARTpool (D-007559-01, D-007559-02,
D-007559-03, D-007559-04) and SiGENOME nontargeting small interfering
RNA (siRNA; D-001206-13-05) were purchased from Open Biosystems.
Cell Lines and Transfections
MCF7 cells were cultured in DMEM containing 10% fetal bovine serum (FBS).
MDA-MB-231, MDA-MB-453, SKBR-3, T47D, and MDA-MB-468 cells were
maintained in RPMI medium containing 10% FBS. Cells were transfected
with plasmids and shRNAs using JetPrime (PolyPlus) and with siRNAs using
the DharmaFECT1 transfection reagent (Open Biosystems).
Antibodies and Chemicals
The anti-RNF5 antibody was described previously (Bromberg et al., 2007;
Delaunay et al., 2008). Other antibodies were obtained from the following sour-
ces: SLC1A5 (Santa Cruz Biotechnology sc-99002 and SigmaHPA035240); vi-
mentin (Sigma HPA001762); SLC38A2 (Santa Cruz sc-67081 and Sigma
HPA035180); phospho-mTOR (2971), phospho-S6K1 (9206), phospho-S6
(4857), phospho-4EBP1 (9459), mTOR (2972), S6K1 (9202), 4EBP1 (9644),
phospho-eIF2a (9721), eIF2a (9722), IREa (3294), PDI (3501), Ero1-La (3264),
calnexin (2433) (all from Cell Signaling Technology); BiP (Santa Cruz sc-
13968); phospho-IREa (Novus Biologicals NB100-2323); p62 (BD Biosciences
610832); V5 (Invitrogen 46-0705); and FLAG (Sigma F1804). BFA was pur-
chased from eBiosciences. TM, TG, cisplatin, doxorubicin, and paclitaxel
were purchased from Sigma.
Immunoprecipitation
Cells were lysed in 50 mM Tris-HCl (pH 8) containing 150 mM NaCl, 1 mM
PMSF, 13 protease inhibitor cocktail (Roche), and 1% Triton X-100 or 0.5%
Nonidet P-40. Cell lysates were incubated with appropriate antibodies for
3 hr at 4C, and then 20 ml of protein A/G agarose beads (Santa Cruz) was
added, and lysates were incubated for an additional 2 hr. Western blots
(WBs) were analyzed and quantified with the aid of the Odyssey imaging scan-
ner (LI-COR Biosciences).
Cell Growth and Clonogenic Assay
For the cell growth assay, cells (2.5 3 105) were seeded in triplicate in 60-mm
plates for 24 hr. Cells were then treated with BFA (2.5 mg/ml) for 18 hr before
harvesting. Viable cells were counted following trypan blue staining. For
the clonogenic assay, cells were plated in six-well plates at 400 cells/2 ml of
medium per well. The medium was not changed during the experiment. After
7–10 days, colonies were fixed, stained with crystal violet, and counted.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.ccell.2015.02.006.ssing high or low RNF5 together with high or low levels of both SLC1A5 and
in levels were either high or low) (p = 0.0021).
reactive, and luminal BCa in a cohort of 747 samples.
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